IP Library › Granted Patent US 12,686,718
Granted Patent B2
US 12,686,718 · App. 18/051,773 · Granted Jul 21, 2026

Targeted binding agents against B7-H1

Inventors: Christophe Queva (Bainbridge Island, WA); Michelle Morrow (Cambridge, GB); Scott Hammond (Olney, MD); Marat Alimzhanov (Wellesley, MA); John Babcook (Burnaby, CA); Ian Foltz (Burnaby, CA); Jaspal Singh Kang (Surrey, CA); Laura Sekirov (Burnaby, CA); Melanie Boyle (Cambridge, GB); Matthieu Chodorge (Cambridge, GB); Ross A. Stewart (Cambridge, GB); Kathleen Ann Mulgrew (Gaithersburg, MD)
C07K16/2827A61K2039/505C07K2317/21C07K2317/33C07K2317/34C07K2317/56C07K2317/565C07K2317/567C07K2317/70C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,686,718
App. No.
18/051,773
Filed
Nov 1, 2022
Granted
Jul 21, 2026
Kind
B2
Art Unit
1644
USPC
424/133.1
Abstract

Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.

Claims (14)

1 . A purified antibody or an antigen-binding fragment thereof, wherein the antibody or antigen-specific fragment thereof is specific for B7-H1 and comprises:

a) a heavy chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence having at least about 85% identity to the amino acid sequence of SEQ ID NO: 52; and

b) a light chain variable domain, wherein the light chain variable domain comprises an amino acid sequence having at least about 90% identity to the amino acid sequence of SEQ ID NO: 57.

2 . The purified antibody or antigen-binding fragment thereof of claim 1 , wherein the heavy chain variable domain comprises an amino acid sequence having greater than 85% identity to the amino acid sequence of SEQ ID NO: 52.

3 . The purified antibody or antigen-binding fragment thereof of claim 1 , wherein the light chain variable domain comprises an amino acid sequence having greater than 90% identity to the amino acid sequence of SEQ ID NO: 57.

4 . The purified antibody or antigen-binding fragment thereof of claim 3 , wherein the light chain variable domain comprises an amino acid sequence having greater than 95% identity to the amino acid sequence of SEQ ID NO: 57.

5 . The purified antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof cross-reacts with cynomolgus monkey B7-H1.

6 . The purified antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof inhibits binding of human B7-H1 to PD-1 expressed on ES-2 cells with an IC50 of less than 0.2 nM.

7 . The purified antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof activates CD4+ T cells in dendritic cell-T-cell mixed lymphocyte assay.

8 . The purified antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof enhances T-cell proliferation in DCMLR assay.

9 . The purified antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof enhances IFN-γ release in DCMLR assay.

10 . A purified antibody or an antigen-binding fragment thereof, wherein the antibody or antigen-specific fragment thereof is specific for B7-H1 and comprises:

a) a heavy chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence having at least about 85% identity to the amino acid sequence of SEQ ID NO: 52 and comprises a CDR1 having the amino acid sequence of SEQ ID NO: 101; and

b) a light chain variable domain, wherein the light chain variable domain comprises an amino acid sequence having at least about 99% identity to the amino acid sequence of SEQ ID NO: 57.

Continuity (6)
Continuation 16519614 · Jul 23, 2019
Continuation 15333683 · Oct 25, 2016
Continuation 14271108 · May 6, 2014
Continuation 13511538 · Nov 24, 2010
Provisional Application 61264061 · Nov 24, 2009
Related Publication 20230235062A1 · Jul 27, 2023
References Cited (29)
US 8217149B2 · Irving et al. · 2012 [cited by applicant]
US 8779108B2 · Queva et al. · 2014 [cited by applicant]
US 9493565B2 · Queva · 2016 [cited by examiner]
US 10092645B2 · Stewart · 2018 [cited by examiner]
US 10400039B2 · Queva et al. · 2019 [cited by applicant]
US 11518809B2 · Queva · 2022 [cited by examiner]
US 20050022688A1 · Asada · 2005 [cited by applicant]
US 20060024607A1 · Tanaka et al. · 2006 [cited by applicant]
US 20090005594A1 · Chen et al. · 2009 [cited by applicant]
EP 1537878A1 · 2008 [cited by applicant]
EP 2172219A1 · 2010 [cited by applicant]
WO 2006133396A1 · 2006 [cited by applicant]
WO 2007149032A1 · 2007 [cited by applicant]
WO 2009089149A1 · 2009 [cited by applicant]
WO 2010077634A1 · 2010 [cited by applicant]
Blank, C., et al., “Blockade of PD-LI (B7-HI) augments human tumor-specific T cell responses in vitro,” Int. J. Cancer, 119(2): 317-327 (2006). [cited by applicant]
Li, N., et al., “Potent Systemic Antitumor Immunity Induced by Vaccination with Chemotactic-Prostate Tumor Associated Antigen Gene-Modified Tumor Cell and Blockade ofB7-HI,” Journal of Clinical Immunology, 27(1): 117-13… [cited by applicant]
Parekh, V., et al., “PD-1/PD-L Blockade Prevents Anergy Induction and Enhances the Anti-Tumor Activities of Glycolipid-Activated Invariant NKT Cells,” The Journal of Immunology, 182(5):2816-2826 (2009). [cited by applicant]
Zhang, L., et al., “PD-1/PD-LI interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model,” Blood, 114(8): 1545-1552 (2009). [cited by applicant]
Li, Betty et al., “Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors”, Clinical Can… [cited by applicant]
Lin, Yin-wel David et al., “The PD-1/PD-LI complex resembles the antigen-binding Fv domains of antibodies and T cell receptors”, PNAS, 105(8): 3011-3016 (2008). [cited by applicant]
Nomi, Takeo et al., “Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer,” 13(7): 2151-2157 (2007). [cited by applicant]
Strome, Scott E. et al., “B7-HI Blockade Auguments Adoptive T-Cell Immunotherapy for Squamous Cell Carcinoma,” Cancer Research, 63: 6501-6505 (2003). [cited by applicant]
Butte, Manish J., et al., “Progreammed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatorv Molecule to Inhibit T Cell Responses,” Immunity 27: 111-122 (2007). [cited by applicant]
Azuma, T., et al., “B7-HI is a ubiquitous antiapoptotic receptor on cancer cells,” Blood 111(7): 3635-3643) 2008. [cited by applicant]
Hohsaka, T., et al., “Incorporation of non-natural amino acids into proteins,” Curr. Opin. Chem. Biol., 6: 809-815 (2009). [cited by applicant]
DeGraaf, A., et al., “Nonatrual Amino Acids for Site-Specific Protein Conugation,” Bioconjugate Chemistry, 20: 1281-1295 (2009). [cited by applicant]
Yan, G., et al., “Genome sequencing and comparison of two nonhuman primate animal models, the cynomolgus and Chinese rhesus macaques,” Nature Biotechnology 29(11): 1019-1023 (2011). [cited by applicant]
International Search Report mailed Feb. 11, 2011, in connection with corresponding International Application No. PCT/US2010/058007. [cited by applicant]